Differential effects of statins and alendronate on cholinesterases in serum and brain of rats

Physiological Research

Volumn 56, Issue 6, 2007, Pages 765-770

  Cibickova L ^a,b   Palicka V ^a   Cibicek N ^a   Cermakova E ^a   Micuda S ^a,b   Bartosova L ^c   Jun, D ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; Alendronate; Alzheimer's disease; Atorvastatin; Cholesterol; Simvastatin

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BONE DENSITY CONSERVATION AGENT; CHOLINESTERASE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; SIMVASTATIN;

ANIMAL; ARTICLE; BLOOD; BRAIN; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; RAT; WISTAR RAT;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BRAIN; BUTYRYLCHOLINESTERASE; CHOLINESTERASES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; RATS; RATS, WISTAR; SIMVASTATIN;

EID: 41749094111     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. ABAD-RODRIGUEZ J, LEDESMA MD, CRAESSAERTS K, PERGA S, MEDINA M, DELACOURTE A, DIGWALL C, DE STROOPER B, DOTTI CG: Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953-960, 2004.
2. ARVANITAKIS Z, LUCAS JA, GRAFF-RADFORD NR: Correlation between serum cholesterol parameters and plasma amyloid beta protein. Neurobiol Aging 21: 96, 2000.
3. BERGMANN CH: Diversification of gamma-secretase activity versus beta-secretase inhibition by cholesterol depletion. Neurobiol Aging 21: 278, 2000.
4. CANIGGA A, GENNARI C, PICCI M: Bisphosphonate lowers cholesterol and total lipid levels in the blood of humans. Boll Soc Ital Biol Sper 50: 1416-1422, 1974.
5. DARVESH S, MARTIN E, WALSH R, ROCKWOOD K: Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 37: 42-49, 2004.
6. ELLMAN GL, COURTNEY KD, ANDRES VL, FEATHERSTONE RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95, 1961.
7. FASSBENDER K, SIMONS M, BERGMANN C, STROICK M, LUTJOHANN D, KELLER P, RUNZ H, KUHL S, BERTSCH T, VON BERGMANN K, HENNERICI M, BEYREUTHER K, HARTMANN T: Simvastatin strongly reduces levels of Alzheimers disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-5861, 2001.
8. HU W, GRAY NW, BRIMIJOIN S: Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem 86: 470-478, 2003.
9. GRUTZENDLER J, MORRIS JC: Cholinesterase inhibitors for Alzheimer's Disease. Drugs 61: 41-52, 2001.
10. KUO YM, EMMERLING MR, BISGAIER CL, ESSENBURG AD, LAMPERT HC, DRUMM D, ROHER AE: Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A-beta 1-42 levels. Biochem Biophys Res Commun 252: 711-715, 1998.
11. LOCATELLI S, LUTJOHANN D, SCHMIDT HH, OTTO C, BEISIEGEL U, VON BERGMANN K: Reduction of plasma 24-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59: 213-216, 2002.
12. MUACEVIC-KATANEDA D, BRADAMANTE V, REINEC Z, SUCIC Z, POLJICAIN T, BUSLJETA I, METELKO Z: Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Arzneimittelforschung 55: 271-275, 2005.
13. PATOČKA J, KUČA K, JUN D: Acetylcholinesterase and butyrylcholinesterase - important enzymes of human body. Acta Medica (Hradec Králové) 47: 215-228, 2004.
14. PETANCESKA SS, DEROSA S, OLM V, DIAZ N, SHARMA A, THOMAS-BRYANT T: Statin therapy for Alzheimer's disease. Will it work? J Mol Sci 16: 155-161, 2002.
15. REA TD, BRITNER JC, PSATY BM, FITZPATRICK AL, LOPEZ OL, NEWMAN AB, HAZZARD WR, ZANDI PP, BURKE GL, LYKETSOS CG, BERNICK C, KULLER LH: Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 62: 1047-1051, 2005.
16. REZKA AA, RODAN GA: Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 4: 711-719, 2004.
17. ROCKWOOD K, KIRKLAND S, HOGAN DB, MACKNIGHT C, MERRY H, VERREAULT R, WOLFSON C, MCDOWELL I: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59: 223-227, 2002.
18. SIMONS S, KELLER P, DE STROOPER B, BEYREUTHER K, DOTTI CG, SIMONS K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95: 6460-6464, 1998.
19. SPARKS DL: Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 17: 291-299, 1996.
20. SPARKS DL, CONNOR DJ, BROWNE PJ, LOPEZ JE, SABBAGH MN: HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 6: 324-331, 2002.
21. WOLOZIN B, KELLMAN W, RUOSSEAU, CELESIA G, SIEGEL G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443, 2000.
22. ZAMRINI E, MCGWIN G, ROSEMAN JM: Association between statin use and Alzheimer's disease. Neuroepidemiology 23: 94-98, 2004.
23. ZANDI PP, SPARKS DL, KHACHATURIAN AS, TSCHANZ J, NORTON M, STEINBERG M, WELSH-BOHMER KA, BREITNER JC: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache cohort study. Arch Gen Psychiatry 62: 217-224, 2005.